TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25854875
Drug: SSRIs treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs treatment (6-week duration)
Study: 24504810
Drug: Abatacept (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (standard weight-tiered dose, approximating 10 mg/kg)
Study: 24504810
Drug: Abatacept (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (30 mg/kg for 3 months, then standard weight-tiered dose)
Study: 10363889
Drug: Polytetrafluoroethylene Patch
Normalized name: polytetrafluoroethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polytetrafluoroethylene Patch Closure (PTFE)
Study: 9510277
Drug: Vein Patch
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vein Patch Closure (VPC)
Study: 508508
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of metronidazole (500 mg)
Study: 508508
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of metronidazole (500 mg)
Study: 508508
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of metronidazole (500 mg)
Study: 30801359
Drug: Bilateral ultrasound-guided
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ultrasound-guided erector spinae plane block using 20 mL of bupivacaine 0.25% on each side
Study: 30801359
Drug: Bilateral sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral sham erector spinae plane block using 1 mL of normal saline
Study: 29728074
Drug: Varenicline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline plus 18 mg/mL nicotine e‐cigarette
Study: 9531251
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg/d + Ticlopidine 2X250 mg/d (Group A)
Study: 9531251
Drug: Ticlopidine 2X250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 2X250 mg/d (Group B)
Study: 7980260
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg bd for a minimum of 5 pre-operative days, then intravenously for 2 postoperative days)
Study: 7980260
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no cimetidine treatment)
Study: 31754119
Drug: Transmitted drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmitted drug resistance (TDR)
Study: 31754119
Drug: Pre-treatment HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment HIV resistance testing
Study: 23733467
Drug: Metronidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (500 mg thrice daily)
Study: 21791363
Drug: Left Ventricular
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left Ventricular Cardiac Resynchronization Therapy (LV CRT)
Study: 21791363
Drug: Biventricular Cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biventricular Cardiac Resynchronization Therapy (Biventricular CRT)
Study: 8092830
Drug: Imipenem monotherapy
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem monotherapy
Study: 3382463
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or initial non-drug investigation
Study: 8201963
Drug: L-phenylalanine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-phenylalanine (10 g)
Study: 30170260
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) - 385.6 mg EPA and 81.2 mg DHA/capsule, n=33
Study: 30170260
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid (DHA) - 417.8 mg DHA and 50.8 mg EPA/capsule, n=33
Study: 29132734
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 mg/day) and Vitamin D3 (50,000 IU every two weeks) for 8 weeks
Study: 24123041
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m²) plus carboplatin (AUC=6 mg/ml min)
Study: 24123041
Drug: Paclitaxel (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (200 mg/m²) plus carboplatin (AUC=6 mg/ml min)
Study: 21235340
Drug: Diamorphine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine treatment (12 months)
Study: 21235340
Drug: Methadone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone treatment (12 months)
Study: 16514112
Drug: Three-times-weekly (TIW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-times-weekly (TIW) regimen of clarithromycin, ethambutol, and rifampin
Study: 426990
Drug: Thiopentone 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 3.5 mg kg‐1
Study: 7066137
Drug: Etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 0.3 mg kg‐1
Study: 6196556
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg prizidilol
Study: 29383550
Drug: Portal message
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Portal message promoting influenza vaccines
Study: 29383550
Drug: IVR call
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVR call promoting influenza vaccines
Study: 25003289
Drug: Mitomycin-C arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin-C arm of the Radiation Therapy Oncology Group 98-11 trial
Study: 30698316
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (MED)
Study: 20556560
Drug: Tapentadol prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol prolonged release (PR; 100‐250 mg twice daily)
Study: 20556560
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride controlled release (CR; 20‐50 mg twice daily)
Study: 16245247
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy plus interventional percutaneous transluminal renal artery stenting (PTRS)
Study: 12400976
Drug: 160 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/day of megestrol acetate
Study: 12400976
Drug: 320 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg/day of megestrol acetate
Study: 12400976
Drug: 160 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/day and 320 mg/day of megestrol acetate
Study: 10446821
Drug: IVIG group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG group (n = 19), received a commercially available human IgA- and IgM-enriched immunoglobulin preparation (dose, 20 g)
Study: 2114240
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose (100 g)
Study: 2114240
Drug: Supramaximal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supramaximal dose of GHRH (50 micrograms bolus, followed by 100 micrograms/h infusion for 3 h)
Study: 390336
Drug: Levodopa-carbidopa combination
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa-carbidopa combination (Sinemet)
Study: 11991768
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of ginseng root extract (GIN)
Study: 9855767
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no psychorelaxation therapy)
Study: 7534777
Drug: Fluocinonide ointment
Normalized name: Fluocinonide Ointment
DrugBank: Fluocinonide (DB01047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinonide ointment plus prolonged occlusion
Study: 7057051
Drug: Fluocinonide ointment
Normalized name: Fluocinonide Ointment
DrugBank: Fluocinonide (DB01047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinonide ointment
Study: 37870
Drug: Nadolol (beta-blocker),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (beta-blocker), given once daily
Study: 37870
Drug: Propranolol (beta-blocker),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (beta-blocker), given four times daily
Study: 31780346
Drug: CBT‐SE (8-session
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT‐SE (8-session cognitive behaviour therapy group intervention)
Study: 22436337
Drug: Manual interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual interventions (e.g. manipulation, mobilization or soft tissue techniques)
Study: 18766426
Drug: Anakinra (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (1 mg/kg daily, ≤100 mg/day)
Study: 17229548
Drug: Prophylaxis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis with single pre‐surgical dose of two tablets amoxicillin/clavulanate 1000/62.5 mg
Study: 17229548
Drug: Pre‐emptive post‐surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐emptive post‐surgery therapy with two tablets amoxicillin/clavulanate 1000/62.5 mg BID for 5 days
Study: 9757201
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection of granisetron
Study: 9757201
Drug: Intravenous drip
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip infusion of granisetron over 30 minutes
Study: 7525038
Drug: Pamidronate 90
Normalized name: pamidronate 90 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 90 mg every 4 weeks
Study: 7525038
Drug: Pamidronate 30
Normalized name: pamidronate 30 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 30 mg every 2 weeks
Study: 22961714
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion of floxuridine with systemic irinotecan
Study: 8996762
Drug: Indefinite, high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indefinite, high dose HBIG (10,000 mu or 40,000 mu/dose depending on HBV DNA status pretransplant)
Study: 8996762
Drug: Indefinite, high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indefinite, high dose HBIG
Study: 25420455
Drug: MNP +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MNP + Fe (2.5 mg iron as NaFeEDTA)
Study: 22352120
Drug: Metoprolol XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol XL 50 mg + Amlodipine 5 mg
Study: 22352120
Drug: Metoprolol XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol XL 25 mg + Amlodipine 2.5 mg
Study: 22352120
Drug: Metoprolol XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol XL 50 mg
Study: 22352120
Drug: Metoprolol XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol XL 25 mg
Study: 9370141
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (45 mg beta-carotene, 825 mg alpha-tocopherol, and 450 mg ascorbic acid daily for three weeks)
Study: 9370141
Drug: Healthy control
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy control group (N = 10) supplemented with the same doses as BMT(+)
Study: 23111108
Drug: Internet‐administered cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet‐administered cognitive behavior therapy (iCBT) for 9 weeks
Study: 20602280
Drug: Chlorhexidine oral
Normalized name: chlorhexidine Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine oral gel
Study: 18008240
Drug: Single-dose sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose sulfadoxine-pyrimethamine (SP)
Study: 15677374
Drug: Daily iron-folic
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron-folic acid (1 tablet/dose, 20 mg elemental iron and 0.1 mg folic acid/tablet)
Study: 15677374
Drug: Biweekly iron-folic
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly iron-folic acid (2 tablets/dose, 20 mg elemental iron and 0.1 mg folic acid/tablet)
Study: 11981066
Drug: cerivastatin 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: cerivastatin 0.15 mg/day
Study: 28786530
Drug: Teneligliptin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teneligliptin (20 mg) added to canagliflozin (C + T group)
Study: 27165661
Drug: Khat (juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Khat (juice mixed with 45 g of ground khat leaves)
Study: 27165661
Drug: Placebo (33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (33 ml of fruit juice)
Study: 17822770
Drug: Voriconazole 200
Normalized name: voriconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole 200 mg twice daily
Study: 16286177
Drug: Rhythm-control antiarrhythmic
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm-control antiarrhythmic drugs
Study: 10397563
Drug: ddl plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ddl plus 3TC (300 mg/day)
Study: 1963170
Drug: MCP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCP with metergoline (10 mg/day p.o. in 5 divided doses for 4 days before MCP)
Study: 1963170
Drug: MCP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCP with ketanserin (10 mg as a slow 3-min intravenous injection, 5 min before MCP)
Study: 7074794
Drug: verapamil (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil (480 mg/day)
Study: 7074794
Drug: propranolol (160-320
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol (160-320 mg/day)
Study: 30855472
Drug: Variable-rate feedback
Normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable-rate feedback infusion plus demand dosing
Study: 30855472
Drug: Constant-rate background
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant-rate background infusion plus demand dosing
Study: 11939614
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine containing alcohol (0.8 g/kg)
Study: 9637639
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion (2.5 microg/ml, 10 ng x kg(‐1) x min(‐1))
Study: 9637639
Drug: Ephedrine infusion
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine infusion (5 mg/ml, 50 microg x kg(‐1) x min(‐1))
Study: 28490322
Drug: Video Game
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Video Game Therapy (VGT)
Study: 21146460
Drug: CVD 909
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 909 vaccine
Study: 16776759
Drug: Direct laser
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct laser treatment
Study: 9262037
Drug: Tetrachlorodecaoxide (TCDO),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrachlorodecaoxide (TCDO), 10 ml, twice daily, swish and swallow, for 7 days
Study: 30853771
Drug: Active CAMBRA
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active CAMBRA treatment
Study: 1947515
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as actually received
Study: 11915060
Drug: Continuous intrabursal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intrabursal infusion of 0.5% bupivacaine and 2 mg morphine (5 mL bolus and 40 mL maintenance at 0.5 mL/h)
Study: 7796496
Drug: Bolus plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus plus infusion c7E3 Fab
Study: 2194849
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of monoethyl fumarate
Study: 694829
Drug: Heparin analogue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin analogue
Study: 30905157
Drug: FXR agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: FXR agonist GW4064
Study: 11225746
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (Humalog)
Study: 3391871
Drug: Erythromycin acistrate
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin acistrate (EA) 400 mg tid
Study: 21443599
Drug: Alitretinoin 20
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alitretinoin 20 mg, once daily for 14 days
Study: 21443599
Drug: Alitretinoin 40
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alitretinoin 40 mg, once daily for 14 days
Study: 19304097
Drug: Low vacuum
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low vacuum group (vacuum 200 mm Hg, flow rate 20 cc/min)
Study: 19304097
Drug: High vacuum
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High vacuum group (vacuum 400 mm Hg, flow rate 40 cc/min)
Study: 16387508
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (CC and BC)
Study: 16387508
Drug: Overall comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall comparison of CC and BC
Study: 8602598
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 g pectin/d)
Study: 29668213
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of ACE inhibitor or ARB for high-risk patients
Study: 16094663
Drug: Venlafaxine (75-225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (75-225 mg/day)
Study: 24188161
Drug: Milnacipran (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran (100 mg/day)
Study: 11535321
Drug: Twinrix (720
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twinrix (720 EL.U inactivated hepatitis A antigen and 20 mcg recombinant hepatitis B surface antigen per milliliter) on a 0, 1, 6 month schedule
Study: 20002596
Drug: Milnacipran 200
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milnacipran 200 mg/day
Study: 8791036
Drug: Clomipramine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 150 mg/day
Study: 2467447
Drug: Invasive laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive laser therapy (He‐Ne laser irradiation)
Study: 23072263
Drug: Memantine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (15 mg/day for 5 days)
Study: 9272336
Drug: Two-component acellular
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-component acellular vaccine
Study: 26971081
Drug: Sertraline 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 400 mg/day
Study: 29542344
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol valerate daily plus 4 mg medroxyprogesterone acetate (MPA), days 19-30
Study: 29542344
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol valerate daily plus 100 mg micronized progesterone (MP), days 19-30
Study: 29198157
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg C. foetida extract daily
Study: 25675856
Drug: High-fat soup
Normalized name: MALT SOUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat soup preload (0.8 kcal/g; 55% calories from fat)
Study: 23134193
Drug: Acamprosate (666
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (666 mg, 3 times daily, total 1,998 mg/d)
Study: 10220121
Drug: Reboxetine (8‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (8‐10 mg/day)
Study: 11030486
Drug: Paroxetine (20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20‐40 mg/day)
Study: 9352392
Drug: BAY 10‐6734
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 10‐6734 (80 mg)
Study: 9352392
Drug: BAY 10‐6734
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 10‐6734 (300 mg)
Study: 30035585
Drug: Brief strategic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief strategic therapy (BST)
Study: 18036454
Drug: Combined antiplatelet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antiplatelet therapy (aspirin plus clopidogrel)
Study: 12702735
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml of a 6.4 % carbohydrate beverage (GLU trial)
Study: 10680106
Drug: Ringer's solution
Normalized name: Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution (Group R)
Study: 10680106
Drug: 2.5% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% glucose solution (Group G)
Study: 8708587
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment (pravastatin)
Study: 1660502
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran with additional fluid (600 mL)
Study: 28515057
Drug: Early reconstruction
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early reconstruction plus exercise therapy
Study: 27086041
Drug: Monthly oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly oral doses of 60,000 IU of cholecalciferol
Study: 23121378
Drug: Aliskiren (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (300 mg daily)
Study: 21946392
Drug: Olmesartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (40 mg daily)
Study: 17721009
Drug: Lipophilic statins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipophilic statins (atorvastatin, fluvastatin, pitavastatin, simvastatin)
Study: 7741168
Drug: Bacitracin zinc
Normalized name: Bacitracin Zinc
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bacitracin zinc (120,000 U, 10-day treatment)
Study: 7741168
Drug: Bacitracin (120,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacitracin (120,000 U, 10-day treatment)
Study: 26473191
Drug: Targeted anticancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted anticancer agents in Phase III RCTs
Study: 23337270
Drug: Ankle block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ankle block administered before inflation of tourniquet (Group B)